The counts and functions of T cells are important when the assessing treatment efficacy and disease prognosis in patients with diffuse large B-cell lymphoma (DLBCL), according to a study published in the journal Cancer Cell International.
This study comprised 31 patients with DLBCL. The investigators used flow cytometry to detect peripheral lymphocyte subsets, phenotypes, and functions. Overall, the study reported the lymphocyte activities of 18 patients.
The results showed that counts of CD3+, CD4+, and CD8+ T cells as well as those of NK cells were lower in patients with newly diagnosed DLBCL compared with healthy controls. Lymphocyte counts didn’t present significant differences between high-risk (IPI scores 3-5) and low-risk patients (IPI scores 0-2), but CD4+ T cells and CD8+ T cells expressed higher levels of CD28 and HLA-DR, respectively, in patients with IPI scores ranging from 3 to 5, the researchers noted.
The results indicate that both counts and functions of lymphocytes are notably attenuated in patients with DLBCL, particularly those of CD4+ and CD8+ T cells.
“The absolute counts and functions of CD4+, CD8+ T cells, which were significantly lower in patients with DLBCL, gradually recovered after effective treatment. Therefore, combined detection of T cell counts and functions are critically important for administering effective personalized immunotherapy as well as for identifying new prognostic markers or DLBCL,” the researchers concluded.